Search results for "Tatin"

showing 10 items of 700 documents

Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk.

2008

We investigated the effect of atorvastatin monotherapy and combined treatment with atorvastatin and pioglitazone on intima-media thickness, vascular function and the cardiovascular risk profile. In all, 148 patients (76 male, 72 female; aged 61.4±6.5 years; body mass index [BMI] 29.2±4.1 kg/m2; mean±SD) with increased cardiovascular (CV) risk factors were randomised. Intima-media thickness (IMT), the augmentation index (Aix@75), the microvascular response to acetylcholine (LDF), lipid status, and plasma levels of intact proinsulin, adiponectin, interleukin-6 (IL-6), monocyte chemotactic protein-1 (MCP-1), matrix metalloproteinase-9 (MMP-9), sCD40L, P-selectin, tissue plasminogen activator …

MaleEndocrinology Diabetes and MetabolismAtorvastatinBlood lipidsBlood Pressurechemistry.chemical_compoundGermanyAtorvastatinMedicineProspective StudiesSkinUltrasonographyeducation.field_of_studymedicine.diagnostic_testMiddle AgedLipidsTreatment OutcomeCardiovascular DiseasesRadial ArteryDrug Therapy CombinationFemaleInflammation MediatorsCardiology and Cardiovascular Medicinemedicine.drugmedicine.medical_specialtyCarotid Artery CommonPopulationRisk AssessmentDouble-Blind MethodInternal medicineInternal MedicineHumansPyrroleseducationAgedAdiponectinPioglitazonebusiness.industryCholesterolMicrocirculationAtherosclerosisEndocrinologychemistryHeptanoic AcidsThiazolidinedionesHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessLipid profilePioglitazoneLipoproteinDiabetesvascular disease research
researchProduct

Pasireotide treatment reduces cardiometabolic risk in Cushing’s disease patients: an Italian, multicenter study

2018

Purpose: Patients with Cushing’s disease (CD) experience metabolic alterations leading to increased cardiovascular mortality. Recently, the visceral adiposity index (VAI) has been proposed as a marker of visceral adipose tissue dysfunction (ATD) and of the related cardiometabolic risk. We aimed to evaluate the impact of 12-month pasireotide treatment on cardiometabolic risk in CD patients. Methods: This is a multicentre, prospective, and observational study. Sixteen CD patients, referred to the Endocrine Units of the University Hospitals of Messina, Napoli, Padova, and Palermo (Italy), successfully treated with pasireotide for 12 month have been enrolled. In all patients, we assessed anthro…

MaleEndocrinology Diabetes and MetabolismCardiometabolic risk Cushing’s disease hypercortisolism pasireotide visceral adiposity indexLongitudinal StudieDisease030204 cardiovascular system & hematologySettore MED/13 - Endocrinologiachemistry.chemical_compound0302 clinical medicineEndocrinologyRisk FactorsMedicineLongitudinal StudiesProspective StudiesAdiposityFramingham Risk ScoreCushing’s diseaseCushing’s diseaseMiddle AgedPasireotideDiabetes and MetabolismHeart DiseaseItalyAtherosclerosiObesity AbdominalFemaleSomatostatinHumanAdultmedicine.medical_specialtyWaistHeart DiseasesHypercortisolism030209 endocrinology & metabolismIntra-Abdominal Fat03 medical and health sciencesMetabolic DiseasesInternal medicineDiabetes mellitusCardiometabolic risk; Cushing’s disease; Hypercortisolism; Pasireotide; Visceral adiposity index; Endocrinology Diabetes and Metabolism; EndocrinologyHumansPituitary ACTH Hypersecretionbusiness.industryRisk FactorCushing's diseaseAnthropometryAtherosclerosismedicine.diseasePasireotideCardiometabolic riskMetabolic DiseaseVisceral adiposity indexProspective StudiechemistryObservational studybusiness
researchProduct

Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors2 Centimeters.

2019

Abstract Purpose Pancreatic neuroendocrine tumors (pNETs) are frequent in multiple endocrine neoplasia type 1 (MEN1) syndrome. They are usually not surgically treated unless larger than 1 to 2 cm or a growth rate > 0.5 cm per year. Somatostatin analogues represent one of the main therapeutic options in pNETs, but they have never been prospectively investigated in MEN1-related pNETs. The aim of this study was to prospectively evaluate the effectiveness of lanreotide in patients with MEN1-related pNETs < 2 cm. Methods MEN1 patients with 1 or more pNETs < 2 cm of maximal diameter were considered. Study design was prospective observational, comparing patients treated with l…

MaleEndocrinology Diabetes and MetabolismClinical BiochemistryNeuroendocrine tumorsLanreotideBiochemistryGastroenterologychemistry.chemical_compoundEndocrinologyactive surveillance lanreotide MEN1 pancreatic neuroendocrine tumors somatostatin analoguesProspective StudiesProspective cohort studyMultiple endocrine neoplasiasomatostatin analoguesMiddle AgedPrognosisTumor BurdenNeuroendocrine TumorsSomatostatinMEN1Disease ProgressionFemalelanreotideSomatostatinAdultmedicine.medical_specialtyAntineoplastic Agentspancreatic neuroendocrine tumorPeptides CyclicYoung AdultInternal medicinemedicineMultiple Endocrine Neoplasia Type 1HumansMEN1Watchful WaitingAgedCentimeterpancreatic neuroendocrine tumorsbusiness.industryBiochemistry (medical)active surveillancemedicine.diseasePancreatic NeoplasmsEndocrinologychemistryactive surveillance; lanreotide; MEN1; pancreatic neuroendocrine tumors; somatostatin analoguesTumor progressionCase-Control StudiesbusinessFollow-Up StudiesThe Journal of clinical endocrinology and metabolism
researchProduct

Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor

2020

Abstract Purpose To evaluate the antiproliferative activity and safety of nonconventional high doses of somatostatin analogs (HD-SSA) in patients with well-differentiated gastroenteropancreatic (GEP) neuroendocrine tumors (NET) with radiological disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria on a previous treatment. Methods A retrospective analysis of prospectively maintained databases from 13 Italian NET-dedicated centers was performed. Main inclusion criteria were: well-differentiated G1 or G2 GEP-NET, progressive disease on a previous treatment, and subsequent treatment with HD-SSA (either by increased administered dose [dose intensity] or…

MaleEndocrinology Diabetes and MetabolismClinical BiochemistryOctreotideNeuroendocrine tumorsLanreotideBiochemistryGastroenterologychemistry.chemical_compoundEndocrinologyhigh dose80 and overMedicineProspective StudiesProspective cohort studyhigh dose; lanreotide; NET; nonconventional doses; octreotide; somatostatin analogs; Adult; Aged; Aged 80 and over; Female; Follow-Up Studies; Hormones; Humans; Liver Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Prognosis; Prospective Studies; Retrospective Studies; Somatostatin; Cell DifferentiationAged 80 and overLiver NeoplasmsCell DifferentiationMiddle Agednonconventional dosePrognosissomatostatin analogsNeuroendocrine TumorsResponse Evaluation Criteria in Solid TumorsFemalelanreotideSomatostatinmedicine.drugAdultmedicine.medical_specialtyhigh dose; lanreotide; NET; nonconventional doses; octreotide; somatostatin analogsInternal medicinenonconventional dosesHumansAdverse effectAgedRetrospective Studiesbusiness.industryBiochemistry (medical)medicine.diseaseHormonesClinical trialNETEndocrinologychemistrybusinessProgressive diseaseoctreotideFollow-Up Studies
researchProduct

Follistatin as potential therapeutic target in prostate cancer

2012

Follistatin is a single-chain glycosylated protein whose primary function consists in binding and neutralizing some members of the transforming growth factor-β superfamily such as activin and bone morphogenic proteins. Emerging evidence indicates that this molecule may also play a role in the malignant progression of several human tumors including prostate cancer. In particular, recent findings suggest that, in this tumor, follistatin may also contribute to the formation of bone metastasis through multiple mechanisms, some of which are not related to its specific activin or bone morphogenic proteins' inhibitory activity. This review provides insight into the most recent advances in understa…

MaleFollistatinendocrine systemCancer Researchmedicine.medical_specialtyanimal structuresGlycosylated proteinProstate cancerInternal medicinemedicineAnimalsHumansPharmacology (medical)Molecular Targeted TherapyActivin Bone metastasis.Cancer . Follistatin Prostate cancerbiologybusiness.industryProstatic NeoplasmsCancerBone metastasisSUPERFAMILYmedicine.diseaseEndocrinologyOncologyembryonic structuresDisease Progressionbiology.proteinCancer researchbusinesshormones hormone substitutes and hormone antagonistsFunction (biology)FollistatinTransforming growth factor
researchProduct

Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial

2012

Background The effects of different hypolipidemic treatment strategies on emerging atherosclerosis risk factors remain unknown. Materials and methods This is a prespecified analysis of a prospective, randomized, open-label, blinded end point (PROBE) study (ClinicalTrials.gov identifier: NCT01010516). Patients (n = 100) with mixed dyslipidaemia on a standard statin dose who had not achieved lipid targets were randomized to switch to the highest dose of rosuvastatin (40 mg/day) or to add-on-statin extended release nicotinic acid (ER-NA)/laropiprant (LRPT) or to add-on-statin micronized fenofibrate for a total of 3 months. Results Following 3 months of treatment, low-density lipoprotein (LDL) …

MaleIndolesTime FactorsClinical BiochemistryPilot ProjectsPharmacologyBiochemistryGastroenterologychemistry.chemical_compoundFenofibrateRisk FactorsProspective StudiesRosuvastatin CalciumHypolipidemic AgentsSulfonamidesFenofibratebiologyGeneral MedicineMiddle AgedRosuvastatin CalciumC-Reactive ProteinCardiovascular DiseasesDrug Therapy CombinationFemalelipids (amino acids peptides and proteins)Laropiprantmedicine.drugAdultmedicine.medical_specialtyStatinmedicine.drug_classNiacinInternal medicinemedicineHumansRosuvastatinAgedApolipoproteins BDyslipidemiasbusiness.industryCholesterolC-reactive proteinnutritional and metabolic diseasesCholesterol LDLAtherosclerosismedicine.diseaseFluorobenzenesPyrimidineschemistry1-Alkyl-2-acetylglycerophosphocholine Esterasebiology.proteinHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessDyslipidemiaEuropean Journal of Clinical Investigation
researchProduct

Non-granule PSA-NCAM immunoreactive neurons in the rat hippocampus

2002

The polysialylated form of the neural cell adhesion molecule (PSA-NCAM) continues to be expressed in the adult hippocampus, mainly in a subset of neurons located in the innermost portion of the granule cell layer. PSA-NCAM immunoreactive neurons have also been described outside this layer in humans, where they are severely reduced in schizophrenic brains. Given this important clinical implication, we were interested in finding whether similar neurons existed in the adult rat hippocampus and to characterize their distribution, morphology and phenotype. PSA-NCAM immunocytochemistry reveals labeled neurons in the subiculum, fimbria, alveus, hilus, and stratum oriens, lucidum and radiatum of CA…

MaleInterneuronNeural Cell Adhesion Molecule L1Hippocampal formationHippocampusCalbindinImage Processing Computer-AssistedmedicineAnimalsNeuropeptide YFluorescent Antibody Technique IndirectNeural Cell Adhesion MoleculesMolecular Biologygamma-Aminobutyric AcidNeuronsbiologyGeneral NeuroscienceSubiculumGranule cellImmunohistochemistryRatsPhenotypemedicine.anatomical_structurenervous systemSialic Acidsbiology.proteinNeural cell adhesion moleculeNeurology (clinical)CalretininSomatostatinNeuroscienceParvalbuminDevelopmental BiologyBrain Research
researchProduct

Muscle-Related Polymorphisms (MSTN rs1805086 and ACTN3 rs1815739) Are Not Associated with Exceptional Longevity in Japanese Centenarians

2016

Myostatin (MSTN) and α-actinin-3 (ACTN3) genes are potentially associated with preservation of muscle mass and oxidative capacity, respectively. To explore the possible role of these genes in exceptional longevity (EL), the allele/genotype frequency distribution of two polymorphisms in MSTN (rs1805086, K153R) and ACTN3 (rs1815739, R577X) was studied in Japanese centenarians of both sexes (n = 742) and healthy controls (n = 814). The rs1805086 R-allele (theoretically associated with muscle mass preservation at the expense of oxidative capacity) was virtually absent in the two groups, where genotype distributions were virtually identical. Likewise, no differences in allele (p = 0.838 (women);…

MaleMetabolic Processes0301 basic medicineAgingHeredityPhysiologyAging and Cancerlcsh:MedicinePolimorfismo genéticoGenética humanaBiochemistry0302 clinical medicineGene FrequencyJapanPolymorphism (computer science)GenotypeMedicine and Health SciencesMorphogenesisActininlcsh:ScienceMusculoskeletal SystemProtein Metabolismmedia_commonGeneticseducation.field_of_studyMultidisciplinaryMusclesCancer Risk FactorsLongevityMuscle DifferentiationGenetic MappingOncologyPopulation SurveillanceFemaleAnatomyResearch ArticleAsian Continental Ancestry Groupmedicine.medical_specialtyGenotypemedia_common.quotation_subjectLongevityAncianoPopulationMuscle TissueVariant GenotypesBiology03 medical and health sciencesAsian PeopleInternal medicineGeneticsmedicineHumansAlleleeducationAllele frequencyAllelesGenetic Association StudiesPolymorphism Geneticlcsh:RBiology and Life SciencesMyostatinGenotype frequencyBiological TissueMetabolism030104 developmental biologyEndocrinologySkeletal MusclesLongevidadlcsh:QPhysiological ProcessesXX GenotypeOrganism Development030217 neurology & neurosurgeryDevelopmental BiologyPLOS ONE
researchProduct

Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germa…

2021

Abstract Background The long-acting somatostatin analog lanreotide autogel is effective in the treatment of patients with neuroendocrine tumors. Objective To evaluate the long-term treatment response in patients with neuroendocrine tumors receiving lanreotide autogel in routine clinical practice. Methods Non-interventional, 24-month study in patients with neuroendocrine tumors treated with lanreotide autogel (NCT01840449). Results Patients (n=80) from 26 centers in Germany and Austria were enrolled. Neuroendocrine tumors were mainly grade 1/2, metastasized, intestinal, and associated with carcinoid syndrome; 88.9% had received previous neuroendocrine tumor treatment. Of those, 84.4% had pre…

MaleOncologymedicine.medical_specialtyEndocrinology Diabetes and Metabolismchromogranin AMedizindiarrheacarcinoid syndromeOctreotideAntineoplastic Agents030209 endocrinology & metabolismNeuroendocrine tumorsPeptides CyclicArticleflushing03 medical and health sciences0302 clinical medicineEndocrinologyQuality of lifeGermanyInternal medicineOutcome Assessment Health CareInternal MedicinemedicineClinical endpointHumansAgedMalignant Carcinoid Syndromebiologybusiness.industryChromogranin AGeneral MedicineMiddle Agedmedicine.diseaseNeuroendocrine Tumorsquality of lifeTolerabilityAustria030220 oncology & carcinogenesisbiology.proteinFemaleObservational studySomatostatinbusinessCarcinoid syndromemedicine.drugExperimental and Clinical Endocrinology & Diabetes
researchProduct

Therapeutic sequences in patients with grade 1−2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group

2019

Purpose: Many different treatments are suggested by guidelines to treat grade 1−2 (G1−G2) neuroendocrine tumors (NET). However, a precise therapeutic algorithm has not yet been established. This study aims at identifying and comparing the main therapeutic sequences in G1−G2 NET. Methods: A retrospective observational Italian multicenter study was designed to collect data on therapeutic sequences in NET. Median progression-free survival (PFS) was compared between therapeutic sequences, as well as the number and grade of side effects and the rate of dose reduction/treatment discontinuation. Results: Among 1182 patients with neuroendocrine neoplasia included in the ELIOS database, 131 G1–G2 ga…

MaleOncologymedicine.medical_specialtyHigh-dose somatostatin analogs; neuroendocrine tumors; PRRT; sequence of treatments; somatostatin analogues; targeted therapyLung NeoplasmsDatabases FactualSettore MED/06 - Oncologia MedicaEndocrinology Diabetes and Metabolismmedicine.medical_treatmentAntineoplastic AgentsHigh-dose somatostatin analogNeuroendocrine tumorsOctreotideSomatostatin analogueTargeted therapySettore MED/13 - EndocrinologiaTargeted therapyEndocrinologyNeuroendocrine tumorStomach NeoplasmsInternal medicineDiabetes mellitusIntestinal NeoplasmsSequence of treatmentmedicineHumansEverolimusRetrospective StudiesChemotherapyEverolimusbusiness.industryDisease ManagementMiddle Agedmedicine.diseaseDiscontinuationPancreatic NeoplasmsNeuroendocrine TumorsRadionuclide therapyFemaleObservational studyPRRTSomatostatinbusinessmedicine.drug
researchProduct